logowsbdaily | Thu, 21 Oct 2021 07:34:43 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Cassava Sciences, Inc.
(SAVA)

Cassava Sciences, Inc.
7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc.... Read More

Summary & Charts

Price$ 47.50-2.66 (-5.31%)
Day's Range$ 47.23 - 51.35 
Previous Close$ 50.16
Market Cap$ 1.39B USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqGS
IndustryBiotechnology
SectorHealthcare
Volume3.75M
Avg. Volume (20 day)6.72M
Rel. Volume (20 day)0.56
Rel. Volume (3 month)0.45
RatingB+Buy
DCFN/AStrong Buy
Debt/Equity1.75 %Neutral
ROE-9.74 %Neutral
ROA-5.84 %Neutral
P/E-115.61 %Strong Sell
P/B6.86 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Oct 19, 2021$ 50.08$ 51.35$ 47.23$ 47.50-2.663,753,0980.560.452
Oct 18, 2021$ 49.99$ 52.64$ 49.17$ 50.16+0.473,354,0360.490.412
Oct 15, 2021$ 54.00$ 54.00$ 49.60$ 49.69-3.683,763,9090.550.476
Oct 14, 2021$ 53.09$ 57.20$ 52.25$ 53.37-1.623,608,5890.520.4521
Oct 13, 2021$ 52.41$ 56.59$ 50.55$ 54.99+3.113,678,9480.520.4677
Oct 12, 2021$ 51.31$ 52.51$ 50.14$ 51.88+0.802,131,1340.300.272
Oct 11, 2021$ 51.19$ 52.11$ 47.79$ 51.08-0.413,855,2580.520.491
Oct 08, 2021$ 53.52$ 54.77$ 51.12$ 51.49-2.132,233,6800.300.293
Oct 07, 2021$ 52.94$ 54.56$ 50.25$ 53.62+1.113,950,7450.510.524
Oct 06, 2021$ 56.88$ 59.98$ 52.13$ 52.51-4.666,102,0040.770.809
Oct 05, 2021$ 54.95$ 57.47$ 54.74$ 57.17+2.863,384,9730.420.456
Oct 04, 2021$ 59.41$ 61.67$ 54.24$ 54.31-6.214,190,4970.510.555
Oct 01, 2021$ 61.45$ 61.93$ 56.64$ 60.52-1.564,193,7240.450.5521
Sep 30, 2021$ 63.00$ 63.52$ 60.04$ 62.08-0.064,274,0200.450.5510
Sep 29, 2021$ 66.00$ 67.58$ 60.07$ 62.14-2.856,966,5850.720.895
Sep 28, 2021$ 65.54$ 67.88$ 61.68$ 64.99-3.548,796,5990.871.135
Sep 27, 2021$ 62.14$ 70.27$ 61.90$ 68.53+6.5910,942,6661.051.4137
Sep 24, 2021$ 59.40$ 66.68$ 58.15$ 61.94+1.8215,004,1371.241.9424
Sep 23, 2021$ 50.37$ 62.67$ 50.33$ 60.12+7.8116,498,0831.312.1632
Sep 22, 2021$ 59.03$ 60.60$ 48.83$ 52.31-0.5523,777,6661.803.1737

News

The latest news about Cassava Sciences, Inc. (SAVA).

Accesswire | 2021-10-15 05:45:00
NEW YORK, NY / ACCESSWIRE / October 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
Newsfile Corp | 2021-10-14 16:08:00
Los Angeles, California--(Newsfile Corp. - October 14, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
Accesswire | 2021-10-13 17:30:00
NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
Newsfile Corp | 2021-10-13 14:32:00
San Francisco, California--(Newsfile Corp. - October 13, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concer
PRNewsWire | 2021-10-13 12:00:00
LOS ANGELES, Oct. 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Class Period: September 14, 2020 and August 27, 2021 Lead Plaintiff Deadline: October 26, 2021  If you wish to serve as lead plaintiff of the Cassava lawsuit, you can submit your contact information at https://www.glancylaw.com/cases/cassava-sciences-inc/.
Newsfile Corp | 2021-10-12 20:01:00
Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").CLICK HERE TO SUBMIT YOUR CASSAVA LOSSESLEAD PLAINTIFF DEADLINE: October 26, 2021CLASS PERIOD: ...
Accesswire | 2021-10-12 17:15:00
NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-11-08BMO-0.15----------
2021-08-03BMO-0.11-0.1318.18%------
2021-04-21BMO-0.1-0.0910%------
2020-11-09BMO-0.07-0.0614.29%------
2020-08-12BMO-0.06-0.0516.67%------
2020-05-06BMO------------
2020-03-26BMO-0.13-0.0838.47%------
2019-10-29BMO-0.13-0.0469.24%------

Due Diligences

These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.

thumbnail
$SAVA Cassava Sciences: Backgrounder for those curious about the story

I sometimes adopt a single stock that I find to be an interesting story to follow. Here is a summary of why I find SAVA to be my current one. # tl;dr * Alzheimer’s common, and lacks a cure. * SAVA is a high risk, high IV, biotech stock: an all-in play on their Alzheimer drug candidate. * SAVA was... Read More

35 comments | 57 votes
thumbnail
SAVA. Cause. More. Wrinkle.

TLDR: At the end of the post. **Associate Professor of Internal Medicine and, more importantly, a certified SAVAge here:** First, I've sent my LinkedIn profile, institutional email, and Institutional Profile to the mods to verify my credentials. Verification of credentials was a big concern... Read More

SAVA is primed for a strong MOVE

Shorts are getting scared on SAVA. Data was solid yesterday but stock price got manipulated down by shorts. **The BEST RESULTS EVER FOR AN ALZHEIMERS DRUG**. More news is coming with the company enlisting patients for Phase 3 Trials. Bio-data to be released from the 12mon data report. Lawsuit deadl... Read More

Top Discussions

These are the top discussions over the last 24-hours that mention the SAVA stock ticker symbol.


Unusual Option Activity

Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.

TypeStrikeExp DateDTEBidAskLastVolumeOpen InterestVol/OIIV
CALL$ 52.0010/14/210$ 3.60$ 4.10$ 3.925664451.271.27%
CALL$ 56.0010/14/210$ 1.30$ 1.60$ 1.405532232.481.17%
CALL$ 47.0010/21/217$ 7.80$ 10.80$ 6.9044202.201.30%
CALL$ 53.0010/21/217$ 4.50$ 5.20$ 4.901541131.361.12%
CALL$ 55.0010/21/217$ 3.60$ 4.00$ 3.805022022.491.11%
CALL$ 66.0010/21/217$ 0.80$ 1.05$ 1.00100205.001.17%
CALL$ 100.0010/21/217$ 0.10$ 0.15$ 0.15128452.841.79%
PUT$ 39.0010/21/217$ 0.25$ 0.35$ 0.30264743.571.45%
PUT$ 46.0010/21/217$ 0.85$ 1.05$ 1.0590541.671.24%
PUT$ 48.0010/21/217$ 0.90$ 1.60$ 1.3594741.271.17%
PUT$ 52.0010/21/217$ 2.40$ 2.60$ 2.7588501.761.14%
PUT$ 53.0010/21/217$ 2.80$ 3.10$ 2.9586621.391.14%
PUT$ 54.0010/21/217$ 3.10$ 3.50$ 3.35104522.001.11%
PUT$ 55.0010/21/217$ 3.50$ 4.00$ 3.861721131.521.09%
CALL$ 48.0010/28/2114$ 7.80$ 11.30$ 8.9093303.101.25%
CALL$ 49.0010/28/2114$ 7.60$ 9.20$ 6.80133642.081.11%
CALL$ 54.0010/28/2114$ 5.10$ 6.70$ 5.60100551.821.19%
CALL$ 57.0010/28/2114$ 4.20$ 4.90$ 4.6047321.471.18%
CALL$ 62.0010/28/2114$ 2.75$ 3.30$ 2.8532112.911.21%
CALL$ 67.0010/28/2114$ 1.35$ 2.25$ 1.8961222.771.18%
PUT$ 39.0010/28/2114$ 0.70$ 1.90$ 0.9539162.441.64%
PUT$ 51.0010/28/2114$ 3.50$ 3.80$ 3.80302565.391.23%
PUT$ 52.0010/28/2114$ 4.00$ 4.30$ 4.153081003.081.24%
PUT$ 53.0010/28/2114$ 4.30$ 6.70$ 4.6748341.411.44%
PUT$ 54.0010/28/2114$ 4.70$ 5.70$ 5.3068106.801.25%
PUT$ 67.0010/28/2114$ 13.20$ 14.80$ 17.4021131.621.23%
CALL$ 54.0011/04/2121$ 6.40$ 7.90$ 7.3198195.161.22%
CALL$ 55.0011/04/2121$ 6.60$ 7.50$ 6.843272712.111.29%
CALL$ 60.0011/04/2121$ 4.70$ 5.00$ 4.80149642.331.23%
PUT$ 48.0011/04/2121$ 2.45$ 5.50$ 4.481,0101759.411.35%
CALL$ 175.0001/20/2298$ 0.75$ 1.45$ 1.47102502.041.29%
CALL$ 145.0001/19/23462$ 11.90$ 14.00$ 13.8094651.451.13%
Last Updated: Wed, 13 Oct 2021 23:27 EST

Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Fri, 30 Jul 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.